The American Journal of Managed Care1d
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Medscape2d
Intravenous to Subcutaneous Infliximab Switch Shows Promise in IBD Management
Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
centerforbiosimilars6d
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...